has approved the acquisition of approximately 2% stake in Biocon Biologics from employees and other shareholders via a preferential allotment. The company will issue up to 87.9 lakh shares at ₹376.16 each, aggregating to approximately ₹330.7 crore. The transaction is subject to requisite approvals and is intended to consolidate Biocon's ownership in its subsidiary Biocon Biologics. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.